IFN-γ or CD8 T cell expansion, migration, and leads to apoptosis of cells of a solid tumor

Journal of Immunology

Volumn 177, Issue 5, 2006, Pages 3004-3011

  Hollenbaugh, Joseph A ^a,b,c   Dutton, Richard W ^a  

^a TRUDEAU INSTITUTE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c SIDNEY KIMMEL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD11B ANTIGEN; CD8 ANTIGEN; CELL PROTEIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PROTEIN GR1; UNCLASSIFIED DRUG; CHEMOKINE; INDUCIBLE NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOSTASIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE 1; HOST CELL; LYMPHOCYTE MIGRATION; LYMPHOID ORGAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR CELL; TUMOR REJECTION; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; CYTOLOGY; GENETICS; METABOLISM; MOUSE MUTANT; NEOPLASM; PATHOLOGY;

ANIMALS; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINES; INTERFERON TYPE II; MICE; MICE, KNOCKOUT; NEOPLASMS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II;

EID: 33747803970     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.5.3004     Document Type: Article

References (41)

1. Wick, M., P. Dubey, H. Koeppen, C. T. Siegel, P. E. Fields, L. Chen, J. A. Bluestone, and H. Schreiber. 1997. Antigenic cancer cells grow progresssively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 186: 229-238.
2. Pardoll, D. 2003. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21: 807-839.
3. McIntosh, M. W., C. Drescher, B. Karlan, N. Scholler, N. Urban, K. E. Hellstrom, and I. Hellstrom. 2004. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol. Oncol. 95: 9-15.
4. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99: 16168-16173.
5. Hughes, M. S., Y. Y. Yu, M. E. Dudley, Z. Zheng, P. F. Robbins, Y. Li, J. Wunderlich, R. G. Hawley, M. Moayeri, S. A. Rosenberg, and R. A. Morgan. 2005. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum. Gene Ther. 16: 457-472.
6. Huang, J., H. T. Khong, M. E. Dudley, M. El-Gamil, Y. F. Li, S. A. Rosenberg, and P. F. Robbins. 2005. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J. Immunother. 28: 258-267.
7. Fong, L., and E. G. Engleman. 2000. Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 18: 245-273.
8. Brossart, P., S. Wirths, W. Brugger, and L. Kanz. 2001. Dendritic cells in cancer vaccines. Exp. Hematol. 29: 1247-1255.
9. Merad, M., T. Sugie, E. G. Engleman, and L. Fong. 2002. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 99: 1676-1682.
10. Labarriere, N., L. Bretaudeau, N. Gervois, M. Bodinier, G. Bougras, E. Diez, F. Lang, M. Gregoire, and F. Jotereau. 2002. Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen. Int. J. Cancer 101: 280-286.
11. Rosenberg, S. A. 1999. A new era of cancer immunotherapy: converting theory to performance. CA Cancer J. Clin. 49: 70-73, 65.
12. Bronte, V., T. Kasic, G. Gri, K. Gallana, G. Borsellino, I. Marigo, L. Battistini, M. Iafrate, T. Prayer-Galetti, F. Pagano, and A. Viola. 2005. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J. Exp. Med. 201: 1257-1268.
13. Moore, M. W., F. R. Carbone, and M. J. Bevan. 1988. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54: 777-785.
14. Helmich, B. K., and R. W. Dutton. 2001. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors. J. Immunol. 166: 6500-6508.
15. Hollenbaugh, J. A., J. B. Reome, M. J. Dobrzanski, and R. W. Dutton. 2004. The rate of the CD8 dependant initial reduction in tumor volume is not limited by contact dependant perform, FasL or TNF mediated cytolysis. J. Immunol. 173: 1738-1743.
16. Schmiegel, W. H., J. Caesar, H. Kalthoff, H. Greten, H. W. Schreiber, and H. G. Thiele. 1988. Antiproliferative effects exerted by recombinant human tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) on human pancreatic tumor cell lines. Pancreas 3: 180-188.
17. Beatty, G. L., and Y. Paterson. 2001. Regulation of tumor growth by IFN-γ in cancer immunotherapy. Immunol. Res. 24: 201-210.
18. Dobrzanski, M. J., J. B. Reome, and R. W. Dutton. 2001. Immunopotentiating role of IFN-γ in early and late stages of type 1 CD8 effector cell-mediated tumor rejection. Clin. Immunol. 98: 70-84.
19. + T cells. Cancer Res. 63: 4095-4100.
20. Carmeliet, P., and R. K. Jain. 2000. Angiogenesis in cancer and other diseases. Nature 407: 249-257.
21. Shi, Q., Q. Xiong, B. Wang, X. Le, N. A. Khan, and K. Xie. 2000. Influence of nitric oxide synthase II gene disruption on tumor growth and metastasis. Cancer Res. 60: 2579-2583.
22. Kashiwagi, S., Y. Izumi, T. Gohongi, Z. N. Demou, L. Xu, P. L. Huang, D. G. Buerk, L. L. Munn, R. K. Jain, and D. Fukumura. 2005. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J. Clin. Invest. 115: 1816-1827.
23. Xie, K., S. Huang, Z. Dong, S. H. Juang, M. Gutman, Q. W. Xie, C. Nathan, and I. J. Fidler. 1995. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J. Exp. Med. 181: 1333-1343.
24. Wadsworth, M. P., B. E. Sobel, D. J. Schneider, and D. J. Taatjes. 2002. Delineation of the evolution of compositional changes in atheroma. Histochem. Cell Biol. 118: 59-68.
25. Nakajima, C., Y. Uekusa, M. Iwasaki, N. Yamaguchi, T. Mukai, P. Gao, M. Tomura, S. Ono, T. Tsujimura, H. Fujiwara, and T. Hamaoka. 2001. A role of interferon-γ (IFN-γ) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-γ-deficient mice. Cancer Res. 61: 3399-3405.
26. Vallera, D. A., P. A. Taylor, S. L. Aukerman, and B. R. Blazar. 1993. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2. Cancer Res. 53: 4273-4280.
27. Hariharan, K., G. Braslawsky, A. Black, S. Raychaudhuri, and N. Hanna. 1995. The induction of cytotoxic T cells and tumor regression by soluble antigen formulation. Cancer Res. 55: 3486-3489.
28. + T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. J. Immunol. 162: 2858-2866.
29. Prevost-Blondel, A., M. Neuenhahn, M. Rawiel, and H. Pircher. 2000. Differential requirement of perform and IFN-γ in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen. Eur. J. Immunol. 30: 2507-2515.
30. Beatty, G. L., and Y. Paterson. 2000. IFN-γ can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J. Immunol. 165: 5502-5508.
31. Ikeda, H., L. J. Old, and R. D. Schreiber. 2002. The roles of IFN γ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13: 95-109.
32. Dominiecki, M. E., G. L. Beatty, Z. K. Pan, P. Neeson, and Y. Paterson. 2004. Tumor sensitivity to IFN-γ is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors. Cancer Immunol. Immunother. 54: 477-488.
33. Cerwenka, A., T. M. Morgan, and R. W. Dutton. 1999. Naive, effector, and memory CD8 T cells in protection against pulmonary influenza virus infection: homing properties rather than initial frequencies are crucial. J. Immunol. 163: 5535-5543.
34. Wiley, J. A., A. Cerwenka, J. R. Harkema, R. W. Dutton, and A. G. Harmsen. 2001. Production of interferon-γ by influenza hemagglutinin-specific CD8 effector T cells influences the development of pulmonary immunopathology. Am. J. Pathol. 158: 119-130.
35. Wei, D., E. L. Richardson, K. Zhu, L. Wang, X. Le, Y. He, S. Huang, and K. Xie. 2003. Direct demonstration of negative regulation of tumor growth and metastasis by host-inducible nitric oxide synthase. Cancer Res. 63: 3855-3859.
36. Xie, K., and S. Huang. 2003. Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency. Free Radic. Biol. Med. 34: 969-986.
37. Gewaltig, M. T., and G. Kojda. 2002. Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc. Res. 55: 250-260.
38. Hu, D. E., S. O. Dyke, A. M. Moore, L. L. Thomsen, and K. M. Brindle. 2004. Tumor cell-derived nitric oxide is involved in the immune-rejection of an immunogenic murine lymphoma. Cancer Res. 64: 152-161.
39. Di Carlo, E., G. Forni, P. Lollini, M. P. Colombo, A. Modesti, and P. Musiani. 2001. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97: 339-345.
40. + T cell ignorance and induction of anti-tumor immunity by peptide-pulsed APC. J. Immunol. 165: 6731-6737.
41. + T cell- and IL-2-dependent mechanism. Immunity 11: 483-493.